Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
Evan M. Bloch(Johns Hopkins University), Kelly A. Gebo(Atrium Health Wake Forest Baptist), Cynthia So‐Osman(Sanquin), Pierre Tiberghien(Inserm), Massimo Franchini(Azienda Ospedaliera Carlo Poma), Brenda J. Grossman(Washington University in St. Louis), David Sullivan(Johns Hopkins University), Shmuel Shoham(Office of Infectious Diseases), Justin E. Juskewitch(Mayo Clinic), Ruchika Goel(Johns Hopkins University), Jonathon W. Senefeld(University of Illinois Urbana-Champaign), Claudia S. Cohn(University of Minnesota), Liise-anne Pirofski(Montefiore Medical Center), Aaron A.R. Tobian(Johns Hopkins University), Jeffrey P. Henderson(Washington University in St. Louis), M. Veronica Dioverti, Arturo Casadevall(Johns Hopkins University), Michael J. Joyner(WinnMed), Daniele Focosi, Robin K. Avery(Johns Hopkins University), Lindsey R. Baden(Brigham and Women's Hospital), Raymund R. Razonable(Mayo Clinic in Florida)
Cited by 52
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi
|Nature Reviews Microbiology|2015|1.3k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
Clinical Practice Guidelines From the AABB
|JAMA|2016|1.1k